<link rel="stylesheet" href="https://bootswatch.com/4/flatly/bootstrap.min.css"><link rel="stylesheet" href="style.css"><script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.16.0/umd/popper.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1">
<div class="header"><div class="top_text"><p id="home">02/07/23</p><p class="summary"><strong> <em>Summary: New data in 4 studies; Expedited timeline in 6 studies; 2 new IND acceptances; 1 new FDA approval.</em> </strong></p></div><div id="images" class="logos"><img src="data:image/png;base64,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" alt="Lexidyne Logo" width="150" class="lex"><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><img src="data:image/png;base64,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" alt="Janssen Logo" width="150" class="jj"> </div></div><h1>Clinical Trials Weekly Digest</h1><br>

<h4><a href="#clinical">Clinical Results Press Releases</a></h4>
<h4><a href="#new_lc">Lung Cancer</a></h4>
<h4><a href="#new_it">Intratumoral</a></h4>
<h4><a href="#new_ct">Cytotoxic</a></h4>
<h4><a href="#new_ia">Immune Activation</a></h4>
<h4><a href="#approvals">Drug Approvals / Applications</a></h4>

<form action="https://getform.io/f/387eb37d-4992-430e-99b3-0bd1f47d1fb2"method="POST" id="interest_form" enctype="multipart/form-data" name="interest_form"><div class="form-group"><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ###### CLINICAL RESULTS ####### -->
<!-- ############################### -->
<!-- ############################### -->

<h2 id="clinical">Clinical Results Press Releases</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Defence</td>
    <td>Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_1" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Anaveon</td>
    <td>Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05578872" target="_blank">OMNIA-1 (NCT05578872)</a></td><td><select class="form-select" id="select_form_2" name="NCT05578872"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Immix Biopharma</td>
    <td>Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03382340" target="_blank">NCT03382340</a></td><td><select class="form-select" id="select_form_3" name="NCT03382340"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Onconova Therapeutics</td>
    <td>Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertibs Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01807546" target="_blank">NCT01807546</a></td><td><select class="form-select" id="select_form_4" name="NCT01807546"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Context Therapeutics</td>
    <td>Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04719273" target="_blank">OATH (NCT04719273)</a></td><td><select class="form-select" id="select_form_5" name="NCT04719273"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Strata Oncology</td>
    <td>Strata Oncology Announces Publication of Study Validating Clinical Utility of Pan-tumor Predictive Biomarker for Checkpoint Inhibitor Immunotherapy Benefit</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03061305" target="_blank">NCT03061305</a></td><td><select class="form-select" id="select_form_6" name="NCT03061305"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Nectin Therapeutics</td>
    <td>Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05378425" target="_blank">NCT05378425</a></td><td><select class="form-select" id="select_form_7" name="NCT05378425"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>J INTS BIO</td>
    <td>J INTS BIO Oral TKI 'JIN-A04' poster presentation of HER2 exon20 insertion mutation in NSCLC</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_8" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo1" class="accordion-toggle">    <td>Everimmune</td>
    <td>French Biotech EverImmune Enters Clinical Stage With Targeted Microbiome Therapy Oncobax AK</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_9" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>

<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW LC ############ -->
<!-- ############################### -->
<!-- ############################### -->

<h3 id="new_lc">NO NEW LUNG CANCER TRIALS</h3><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ######## EXISTING LC ########## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_lc">Existing Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 489 days; Trial completed</strong></td>
    <td>Extensive-stage disease small cell lung cancer</td>
    <td>Jiangsu HengRui Medicine Co. Ltd.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_1">Study Arms</button></td>
    <td>SHR-1210; Apatinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03417895" target="_blank">NCT03417895</a></td><td><select class="form-select" id="select_form_10" name="NCT03417895"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 419 days; Enrollment increased by: 81; Trial completed; Primary Completion Date moved earlier by 127 days</strong></td>
    <td>Advanced or recurrent non-squamous NSCLC</td>
    <td>Beijing Mabworks Biotech Co. Ltd.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_2">Study Arms</button></td>
    <td><p>mil60; Bevacizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_501">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03196986" target="_blank">NCT03196986</a></td><td><select class="form-select" id="select_form_11" name="NCT03196986"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Previously treated and treatment-naive NSCLC</td>
    <td>Spectrum Pharmaceuticals Inc</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_3">Study Arms</button></td>
    <td>Poziotinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03318939" target="_blank">NCT03318939</a></td><td><select class="form-select" id="select_form_12" name="NCT03318939"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 160 days; Trial completed</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>Sumitomo Pharma Oncology Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_4">Study Arms</button></td>
    <td>TP-0903</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02729298" target="_blank">NCT02729298</a></td><td><select class="form-select" id="select_form_13" name="NCT02729298"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Leptomeningeal disease</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_5">Study Arms</button></td>
    <td><p>Biospecimen Collection; Computed Tomography; Lumbar Puncture; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_503">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03025256" target="_blank">NCT03025256</a></td><td><select class="form-select" id="select_form_14" name="NCT03025256"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Metastatic EGFR mutant lung cancer</td>
    <td>Memorial Sloan Kettering Cancer Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_6">Study Arms</button></td>
    <td><p>Dacomitinib; Osimertinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_503">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03810807" target="_blank">NCT03810807</a></td><td><select class="form-select" id="select_form_15" name="NCT03810807"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 1055 days; Enrollment increased by: 92; Trial completed; Primary Completion Date pushed later by 1212 days</strong></td>
    <td>Locally advanced or metastatic non-small cell lung cancer</td>
    <td>Jiangsu HengRui Medicine Co. Ltd.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_7">Study Arms</button></td>
    <td>SHR-1210; Apatinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03083041" target="_blank">NCT03083041</a></td><td><select class="form-select" id="select_form_16" name="NCT03083041"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 457 days; Primary Completion Date pushed later by 273 days</strong></td>
    <td>Treatment-naive locally advanced or metastatic PD-L1 positive NSCLC</td>
    <td>Swiss Group for Clinical Cancer Research</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_8">Study Arms</button></td>
    <td><p>Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03620669" target="_blank">NCT03620669</a></td><td><select class="form-select" id="select_form_17" name="NCT03620669"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 394 days</strong></td>
    <td>Stage I-III non-small cell lung cancer</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_9">Study Arms</button></td>
    <td><p>Cisplatin; Docetaxel; Erlotinib; Erlotinib Hydrochloride; Laboratory Biomarker Analysis</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT00254384" target="_blank">NCT00254384</a></td><td><select class="form-select" id="select_form_18" name="NCT00254384"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Advanced Cancer</td>
    <td>Compugen Ltd</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_10">Study Arms</button></td>
    <td><p>COM701; COM701 with Opdivo (Nivolumab).</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03667716" target="_blank">NCT03667716</a></td><td><select class="form-select" id="select_form_19" name="NCT03667716"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 419 days; Enrollment increased by: 81; Trial completed; Primary Completion Date moved earlier by 127 days</strong></td>
    <td>Advanced or recurrent non-squamous NSCLC</td>
    <td>Beijing Mabworks Biotech Co. Ltd.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_11">Study Arms</button></td>
    <td><p>mil60; Bevacizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03196986" target="_blank">NCT03196986</a></td><td><select class="form-select" id="select_form_20" name="NCT03196986"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 182 days</strong></td>
    <td>Malignant Pleural Mesothelioma</td>
    <td>H. Lee Moffitt Cancer Center and Research Institute</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_12">Study Arms</button></td>
    <td><p>Cisplatin; Methotrexate; Gemcitabine; Lung Cancer Symptom Scale for Mesothelioma Questionnaire</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02611037" target="_blank">NCT02611037</a></td><td><select class="form-select" id="select_form_21" name="NCT02611037"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 212 days; Enrollment decreased by: 27; Changed status from recruiting to active; Primary Completion Date pushed later by 578 days</strong></td>
    <td>Non-small Cell Lung Cancer</td>
    <td>H. Lee Moffitt Cancer Center and Research Institute</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_13">Study Arms</button></td>
    <td><p>Ceritinib; Docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03611738" target="_blank">NCT03611738</a></td><td><select class="form-select" id="select_form_22" name="NCT03611738"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo2" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo2"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 187 days</strong></td>
    <td>Advanced non-small cell lung cancer (NSCLC)</td>
    <td>Janssen Research & Development LLC</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_14">Study Arms</button></td>
    <td><p>Amivantamab; Amivantamab; Lazertinib; Carboplatin; Pemetrexed</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02609776" target="_blank">NCT02609776</a></td><td><select class="form-select" id="select_form_23" name="NCT02609776"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 182 days</strong></td>
    <td>Stage III Unresectable Non-Small Cell Lung Cancer</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_15">Study Arms</button></td>
    <td>MEDI4736; PLACEBO</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02125461" target="_blank">NCT02125461</a></td><td><select class="form-select" id="select_form_24" name="NCT02125461"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 1096 days</strong></td>
    <td>Advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_16">Study Arms</button></td>
    <td><p>Durvalumab (MEDI4736); Paclitaxel + carboplatin; Gemcitabine + cisplatin; Gemcitabine + carboplatin; Pemetrexed + cisplatin; Pemetrexed + carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_505">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03003962" target="_blank">NCT03003962</a></td><td><select class="form-select" id="select_form_25" name="NCT03003962"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 364 days</strong></td>
    <td>Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_17">Study Arms</button></td>
    <td><p>Durvalumab +Tremelimumab; Paclitaxel + carboplatin; Gemcitabine + cisplatin; Gemcitabine + carboplatin; Pemetrexed + cisplatin; Pemetrexed + carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_505">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02542293" target="_blank">NCT02542293</a></td><td><select class="form-select" id="select_form_26" name="NCT02542293"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_1" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>• SHR-1210 200mg IV Q2W and Apatinib 375mg PO QD|• SHR-1210 200mg IV Q2W and Apatinib 375mg PO QD（5 Days on 2 Days off）|• SHR-1210 200mg IV Q2W and Apatinib 375mg PO QD（7 Days on 7 Days off）</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Apatinib; Drug: SHR-1210</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Adverse event of part 1|ORR</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>• Evaluation of adverse event rate according to CTCAE v4.03; • Objective response rate according to RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>on average of of 3 months(First 6 subjects in each arm); 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_2" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>mil60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression intolerable toxicity or withdrawal.|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression intolerable toxicity or withdrawal.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: mil60; Drug: Bevacizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Percentage of patients with complete remission or partial response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_3" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cohort 1: Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC (closed to enrollment)|Cohort 2: Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC (closed to enrollment)|Cohort 3: Treatment naïve patients with EGFR exon 20 insertion-mutant positive NSCLC (fully enrolled)|Cohort 4: Treatment naïve patients with HER2 exon 20 insertion mutant positive NSCLC|Cohort 5: Patients who meet the criteria for enrollment in Cohort 1 to 4 but the enrollment in the respective cohort has been closed|Cohort 6: Patients with acquired EGFR mutation who progressed while on treatment with first-line osimertinib|Cohort 7: Patients with EGFR or HER2 activating mutations</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Poziotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The proportion of subjects who achieve Complete Response (CR) and Partial Response (PR) by the best response from the first dose of poziotinib to the end of study.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_4" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Phase 1a Single daily dose of TP-0903 by oral administration on Days 1-21 of a 28 day cycle||AND||Phase 1b - Upon confirmation of MTD will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.|Phase 1b - Upon confirmation of MTD will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.|Phase 1b - Upon confirmation of MTD will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.|Phase 1b - Upon confirmation of MTD will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.|Phase 1b - Upon confirmation of MTD will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TP-0903</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A DLT is defined as any one of the following events observed within Cycle 1:; Grade 3 or greater febrile neutropenia Grade 4 ANC for 7 or greater consecutive days Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with clinically significant bleeding or that requires a platelet transfusion Grade 3 or 4 non-hematologic AEs including nausea vomiting diarrhea and electrolyte imbalances persisting for more than 48 hours despite optimal medical management dosing delays of 2 weeks or greater due to treatment emergent adverse events or related severe laboratory test values</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 (Day 1 through Day 28)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_5" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2 patients also receive nivolumab IV over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days for 18 cycles and then every 28 days (cycles 19 and beyond) in the absence of disease progression or unacceptable toxicity. Patients will have CSF and blood specimen collection on days 1 2 8 of each cycle and end of treatment. Patients undergo CT or PET at baseline cycle 5 and then every 8 weeks. Patients undergo MRI at baseline cycles 3 5 and then every 8 weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Positron Emission Tomography; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab; Procedure: Computed Tomography; Procedure: Lumbar Puncture; Procedure: Biospecimen Collection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events|Recommended dose of combined intrathecal (IT) and intravenous (IV) nivolumab defined as the highest dose for which the posterior probability of toxicity is closest to 30% (dose escalation part)|Overall survival (OS) in patients treated with IT and IV nivolumab (dose expansion part)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The Bayesian modified toxicity probability interval method will be used to find the recommended dose.; Safety and tolerability of treatment will be assessed by vital signs laboratory assessments adverse events and serious adverse events for the safety population. Adverse events will be graded by the Common Terminology Criteria for Adverse Events version 4.0. Categorical measures will be summarized using frequencies and percentages while continuous variables will be summarized using mean standard deviation median minimum and maximum.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 28 days; Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_6" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will begin on combination dacomitinib and osimertinib at the prescribed doses.||A cycle will be 28 days in duration. The study will use a standard 3+3 dose escalation design. Per MD discretion telemedicine visits may be utilized for cycles where imaging is not collected and physical exam vital sign and labs collection will only be required concurrent with imaging visits.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Osimertinib; Drug: Dacomitinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>maximum tolerated dose|Best overall response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"The MTD will be defined as the highest dose at which not more than 1/6 of the patients experience dose limiting toxicity (DLT). DLT is defined as any of the toxicity events described below that occurs within cycle 1 of treatment with the combination of dacomitinib and osimertinib.; Tumor response will be assessed using RECIST 1.1.The NCI Common Terminology Criteria for Adverse Events Version 5 (NCI-CTCAE) will be used to grade toxicities during the trial. Dose-limiting toxicities (DLT""s) are defined as any of the following events occurring during the first cycle of treatment"</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_7" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SHR-1210 200mg IV Q2W and Apatinib 250mg PO QD|SHR-1210 200mg IV Q2W and Apatinib 500mg PO QD|SHR-1210 200mg IV Q2W and Apatinib 375mg PO QD</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Apatinib; Biological: SHR-1210</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1: Incidence and grade of adverse events (AEs) and Serious adverse events (SAEs)|Part 2:Objective response rate (ORR) per RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the proportion of subjects who have achieved complete response (CR) or partial response (PR) according to RECIST 1.1; AEs and SAEs assessed by NCI-CTCAE v4.03</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 6 months; up to 24 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_8" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Durvalumab until progression or unacceptable toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall survival (OS) at 6 months</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OS at 6 months is defined as being alive at 6 months after registration.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At 6 months after registration</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_9" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning within 90 days following definitive surgical resection patients receive erlotinib hydrochloride PO daily for up to 1 year.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Laboratory Biomarker Analysis; Drug: Erlotinib Hydrochloride; Drug: Erlotinib; Drug: Cisplatin; Drug: Docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Rate of grade 3 or greater toxicities (hematologic or non-hematologic)|Changes of EGFR expression (i.e. EGFR modulation) between buccal smears and bronchial tissue</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Agreement will be estimated using the kappa coefficient. An important aspect of this trial is to identify changes in expression of potential biomarkers between buccal smears and bronchial tissues after induction (neoadjuvant) platinum-based therapy in early-stage  resectable non-small cell lung cancers. As part of the primary outcome measures we plan to measure the EGFR expression changes (i.e. EGFR modulation) between buccal smears and bronchial tissues after induction therapy.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 5 years post-treatment; From baseline up to 5 years post-treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_10" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.|COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.|COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC Breast Ovarian Endometrial and Colorectal cancer).|COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast Ovarian Endometrial and Colorectal cancer).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: COM701 with Opdivo (Nivolumab).; Drug: COM701</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs).|Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with nivolumab).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To evaluate the safety profile of COM701 monotherapy and in combination with nivolumab.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 2 year.; DLT evaluation window in the 1st cycle (21 or 28 days).</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_11" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>mil60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression intolerable toxicity or withdrawal.|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression intolerable toxicity or withdrawal.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: mil60; Drug: Bevacizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Percentage of patients with complete remission or partial response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_12" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Transarterial Chemoperfusion treatment with cisplatin (35 mg/m^2) methotrexate (100 mg/m^2) and gemcitabine (1000 mg/m^2).||Patients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.||Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Lung Cancer Symptom Scale for Mesothelioma Questionnaire; Drug: Methotrexate; Drug: Cisplatin; Drug: Gemcitabine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Disease Control Rate (DCR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Disease control rate of transarterial chemoperfusion treatment with cisplatin methotrexate and gemcitabine in patients with unresectable malignant pleural mesothelioma using modified Response Evaluation Criteria in Solid Tumors (RECIST) for mesothelioma. DCR provided as percentage of participants with partial response + percentage of participants with stable disease.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_13" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The design will recruit participants in cohorts of three patients each and will not allow for dose-skipping during escalation. A maximum of 18 participants will be enrolled for the phase I dose escalation. Three ceritinib dose levels have been identified for dose escalation (150 mg 300 mg and 450 mg) plus docetaxel at 75 mg. A backup dose (ceritinib 150 mg with docetaxel at 60 mg) is also prepared in case the three dose levels are too toxic. Therefore four potential dose levels will be used for determination of maximum tolerated dose (MTD). The first cohort will start at dose level 1 (ceritinib 150 mg with docetaxel at 75 mg).||Level -1 Backup Cohort: 150 mg ceritinib; 60 mg/m^2 docetaxel Level 1 Starting Cohort: 150 mg ceritinib; 75 mg/m^2 docetaxel Level 2 Cohort: 300 mg ceritinib; 75 mg/m^2 docetaxel Level 3 Cohort: 450 mg ceritinib; 75 mg/m^2 docetaxel|Treatment at recommended dose. Investigators plan to have 30 patients for the expansion cohort. This will include participants from the dose escalation portion receiving the recommended dose.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Docetaxel; Drug: Ceritinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase I: Maximum Tolerated Dose (MTD)|Phase Ib: Overall Response (OR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OR: Defined as the participant being alive and the tumor size evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on subsequent imaging assessment consistent with a complete response (CR) or partial response (PR). Overall response rates will be calculated with a 2-sided 95% confidence interval (CI). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to  10 mm ( 1 cm). Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions taking as reference the baseline sum diameters.; Maximum tolerated dose corresponding to a risk of dose limiting toxicity (DLT) occurring in 30% of patients.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 months; Up to 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_14" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The first cohort of participants will receive intravenous (IV) infusions of Amivantamab 140 milligram (mg) as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level. Dose escalation will continue until maximum tolerated dose is reached or all planned doses are administered. Participants will receive IV infusion of Amivantamab once weekly during cycle 1 and once every 2 weeks during subsequent cycles (duration of each treatment cycle is 28 days). Participants will receive lazertinib and Amivantamab on Cycle 1 Day 1 (C1D1) prior to initiation of Amivantamab (C1D1) at predefined dose levels based upon observed safety and protocol defined criteria. Lazertinib will be administered daily thereafter on 28-day Amivantamab treatment cycle. In Chemotherapy Combination Cohort participants will receive Amivantamab administered on a 21-day cycle in combination with standard of care carboplatin and pemetrexed.|Participants will receive IV infusion of Amivantamab as monotherapy at Phase 2 dose (RP2D) regimen or in combination lazertinib at the recommended Phase 2 combination dose (RP2CD) regimen as determined in Part 1. The purpose of dose expansion is to further evaluate safety tolerability pharmacokinetic and to assess preliminary efficacy in monotherapy and combination therapy cohorts.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lazertinib; Drug: Carboplatin; Drug: Pemetrexed; Drug: Amivantamab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1: Number of Participants With Dose Limiting Toxicity (DLT)|Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs|Part 2: Overall Response Rate (ORR)|Part 2: Duration of Response (DOR)|Part 2: Percentage of Participants With Clinical Benefit|Trough Serum Concentration (Ctrough) of Amivantamab|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DOR will be calculated as time from initial response of CR (disappearance of all target lesions and non-target lesions. All lymph nodes must be non-pathological in size ([] 10 [mm] short axis) and normalisation of tumour marker levels) or PR (at least a 30 [%] decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits or durable stable disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum diameters while on study and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits) to progressive disease (PD) or death due to underlying disease whichever comes first only for participants who achieve CR or PR.; The Dose Limiting Toxicity (DLT) is based on drug related adverse events and includes unacceptable hematologic toxicity non-hematologic toxicity of Grade 3 or higher or elevations in hepatic enzymes suggestive of drug-induced liver injury.; Clinical benefit rate is defined as the percentage of participants achieving complete response (CR): disappearance of all target lesions and non-target lesions. All lymph nodes must be non-pathological in size (less than [] 10 millimeter [mm] short axis) and normalisation of tumour marker levels or partial response (PR): at least a 30 percent (%) decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits or durable stable disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum diameters while on study and persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.; Overall response rate (ORR) is defined as the percentage of participants who achieve either a CR or PR as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1). CR: disappearance of all target lesions and non-target lesions. All lymph nodes must be non-pathological in size ( 10 mm short axis) and normalisation of tumour marker levels; PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters and Persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.; An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.; Ctrough is the observed serum concentration immediately prior to the next administration.; The AUCtau is the area under the serum concentration-time curve during a dose interval time period (tau)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to EOT Follow Up Period (30 [+7] days after the last dose); Screening up to follow-up (30 [+7] days after the last dose); Up to End of Treatment Follow (EOT) Up Period (30 [+7] days after the last dose); Up to EOT (30 days after last dose); Up to Day 28</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_15" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>MEDI4736 (intravenous infusion)|Placebo (matching placebo for intravenous infusion)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: PLACEBO; Drug: MEDI4736</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OS was defined as the time from the date of randomization until death due to any cause. OS was calculated using the Kaplan-Meier technique.; PFS was defined as the time from randomization until the date of objective disease progression (RECIST 1.1) or death (by any cause in the absence of progression). Progression was defined using RECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions or a measurable increase in a non-target lesion or the appearance of new lesions. PFS was calculated using the Kaplan-Meier technique.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Tumor scans performed at baseline then every ~8 weeks up to 48 weeks then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.; From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_16" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Anti-PD-L1 monoclonal Antibody monotherapy|Standard of Care Platinum-Based chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab (MEDI4736); Drug: Pemetrexed + cisplatin; Drug: Pemetrexed + carboplatin; Drug: Gemcitabine + carboplatin; Drug: Paclitaxel + carboplatin; Drug: Gemcitabine + cisplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The efficacy of Durvalumab therapy compared to SoC in terms of Overall Survival (OS) in all randomized patients|The efficacy of Durvalumab therapy compared to SoC in terms of OS in patients who are at low risk of early mortality (EM)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_17" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)|Standard of Care chemotherapy treatment</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pemetrexed + cisplatin; Drug: Pemetrexed + carboplatin; Drug: Gemcitabine + carboplatin; Biological: Durvalumab +Tremelimumab; Drug: Paclitaxel + carboplatin; Drug: Gemcitabine + cisplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set|OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The OS was defined as the time from the date of randomization until death due to any cause (ie date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From baseline (Day 1 Week 0) until death due to any cause assessed up to the Global cohort DCO date (a maximum of approximately 44 months).; From baseline (Day 1 Week 0) until death due to any cause assessed up to the China cohort DCO date (a maximum of approximately 44 months).</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IT ############ -->
<!-- ############################### -->
<!-- ############################### -->

<h3 id="new_it">NO NEW INTRATUMORAL TRIALS</h3><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_it">Existing Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date pushed later by 731 days</strong></td>
    <td>Basal Cell Nevus Syndrome</td>
    <td>Ascend Biopharmaceuticals Ltd</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_18">Study Arms</button></td>
    <td>ASN-002</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03208296" target="_blank">NCT03208296</a></td><td><select class="form-select" id="select_form_27" name="NCT03208296"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo3" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo3"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date pushed later by 242 days</strong></td>
    <td>Advanced hepatocellular carcinoma</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_19">Study Arms</button></td>
    <td><p>lenvatinib; pembrolizumab; saline placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_506">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03713593" target="_blank">NCT03713593</a></td><td><select class="form-select" id="select_form_28" name="NCT03713593"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_18" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs weekly x 3 i.e. weeks 1 2 and 3|Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs weekly x 3 i.e. weeks 1 2 and 3|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs weekly x 3 i.e. weeks 1 2 and 3</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: ASN-002</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety of ASN-002 will be studied in terms of AEs reported in individuals with Basal Cell Nevus Syndrome (BCNS) receiving ASN-002 using CTCAE 4.03.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Clinical safety will assessed in terms of changes in vital signs AEs serious AEs (SAEs) laboratory abnormalities and withdrawals from study. Local skin and injection site reactions will be assessed in detail scoring erythema ulceration pain and overall severity as none mild moderate or severe using protocol-specific modifications of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>The assessment will be conducted at every visit after first dose week1 week2 week 3 Months1 2 3 4 and at Month 6.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_19" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight 60 kg) orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight 60 kg) orally QD plus saline placebo by IV infusion on Day 1 Q3W. Saline placebo will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: pembrolizumab; Drug: saline placebo; Drug: lenvatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time from randomization to the first documented disease progression or death due to any cause whichever occurs first. Responses are according to the RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 has been modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.; OS is the time from randomization to death due to any cause.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 44 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW  CT ########### -->
<!-- ############################### -->
<!-- ############################### -->

<h3 id="new_ct">NO NEW CYTOTOXIC TRIALS</h3><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING CT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ct">Existing Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Primary Completion Date moved earlier by 1118 days</strong></td>
    <td>Epstein Barr Virus (EBV) Disorder including either Hodgkin Lymphoma or non-Hodgkin Lymphoma or Lymphoepithelioma or severe chronic active EBV infection syndrome (SCAEBV) or Leiomyosarcoma</td>
    <td>Catherine Bollard</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_20">Study Arms</button></td>
    <td>LMP1/2 CTLs (Group A); LMP1/2 CTLs (Group B)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01956084" target="_blank">NCT01956084</a></td><td><select class="form-select" id="select_form_29" name="NCT01956084"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days; Primary Completion Date moved earlier by 237 days</strong></td>
    <td>EBV; CMV; Adenovirus</td>
    <td>Catherine Bollard</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_21">Study Arms</button></td>
    <td>CTL for CMV seropositive donors; CTL for CMV nave donors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01945814" target="_blank">NCT01945814</a></td><td><select class="form-select" id="select_form_30" name="NCT01945814"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Mesothelin positive pancreatic cancer that has spread to other places in the body (advanced)</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_22">Study Arms</button></td>
    <td><p>Anetumab Ravtansine; Biopsy; Biospecimen Collection; Gemcitabine Hydrochloride; Ipilimumab; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_508">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03816358" target="_blank">NCT03816358</a></td><td><select class="form-select" id="select_form_31" name="NCT03816358"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days; Primary Completion Date moved earlier by 237 days</strong></td>
    <td>EBV; CMV; Adenovirus</td>
    <td>Catherine Bollard</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_23">Study Arms</button></td>
    <td>CTL for CMV seropositive donors; CTL for CMV nave donors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01945814" target="_blank">NCT01945814</a></td><td><select class="form-select" id="select_form_32" name="NCT01945814"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 184 days; Primary Completion Date pushed later by 120 days</strong></td>
    <td>Newly diagnosed high-grade gliomas</td>
    <td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_24">Study Arms</button></td>
    <td><p>AdV-tk; Valacyclovir; Radiation; Temozolomide; Nivolumab; Laboratory Biomarker Analysis</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03576612" target="_blank">NCT03576612</a></td><td><select class="form-select" id="select_form_33" name="NCT03576612"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo4" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_20" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receiving CTLs as adjunctive therapy following allogeneic stem transplant|Patients receiving CTLs in relapse following allogeneic stem cell transplant</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: LMP1/2 CTLs (Group B); Drug: LMP1/2 CTLs (Group A)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of patients with dose limiting toxicity (DLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Toxicity will be evaluated according to NCI Common Terminology Criteria for Adverse Events scale version 2.0. DLT will be defined as development of any toxicity scored as Grade 3 or 4 and primarily related to the CTL infusion.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_21" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65) EBV (LMP2 EBNA1) and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion) followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65) EBV (LMP2 EBNA1) and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion) followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: CTL for CMV naïve donors; Drug: CTL for CMV seropositive donors</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Assessments of patients with adverse events after mukti-virus specific CTL infusion.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary endpoint for this phase I trial are feasibility and safety. Safety of administration of CTLs is 45 days. The safety endpoint will be defined as acute GvHD grades III-IV within 45 days of the last dose of CTLs or grades 3-5 infusion-related adverse events within 45 days of the last CTL dose or grades 4-5 non-hematological adverse events within 45 days of the last CTL dose and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>45 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_22" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive ipilimumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of cycles 2-4. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive gemcitabine hydrochloride over 30-40 minutes on days 1 and 8. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Ipilimumab; Biological: Nivolumab; Procedure: Biopsy; Drug: Gemcitabine Hydrochloride; Biological: Anetumab Ravtansine; Procedure: Biospecimen Collection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>This study will follow a 3+3 dose escalation design.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30-37 days post treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_23" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65) EBV (LMP2 EBNA1) and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion) followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65) EBV (LMP2 EBNA1) and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion) followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: CTL for CMV naïve donors; Drug: CTL for CMV seropositive donors</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Assessments of patients with adverse events after mukti-virus specific CTL infusion.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary endpoint for this phase I trial are feasibility and safety. Safety of administration of CTLs is 45 days. The safety endpoint will be defined as acute GvHD grades III-IV within 45 days of the last dose of CTLs or grades 3-5 infusion-related adverse events within 45 days of the last CTL dose or grades 4-5 non-hematological adverse events within 45 days of the last CTL dose and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>45 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_24" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>After confirmation of high grade glioma AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.|After confirmation of high grade glioma AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Valacyclovir; Other: Laboratory Biomarker Analysis; Radiation: Radiation; Drug: Temozolomide; Biological: Nivolumab; Biological: AdV-tk</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 will be used for scoring toxicity and adverse events. The severity and frequency of toxicity will be tabulated by the tested dose or doses using descriptive statistics. The proportions of subjects who experienced grade 3 or above toxicities will be estimated along with 95% confidence intervals by each type of toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IA ############ -->
<!-- ############################### -->
<!-- ############################### -->

<h3 id="new_ia">NO NEW IMMUNE ACTIVATION TRIALS</h3><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IA ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ia">Existing Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Enrollment decreased by: 17; Changed status from recruiting to active</strong></td>
    <td>Multiple Myeloma</td>
    <td>Baylor College of Medicine</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_25">Study Arms</button></td>
    <td>CVD908ssb-TXSVN</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03762291" target="_blank">NCT03762291</a></td><td><select class="form-select" id="select_form_34" name="NCT03762291"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 366 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Castration-resistant prostate cancer that has spread to other places in the body</td>
    <td>University of Southern California</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_26">Study Arms</button></td>
    <td><p>Enzalutamide; Laboratory Biomarker Analysis; Radium Ra 223 Dichloride</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_510">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03344211" target="_blank">NCT03344211</a></td><td><select class="form-select" id="select_form_35" name="NCT03344211"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo5" class="accordion-toggle">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_25" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>3 different dosing schedules will be studied (3+3 design). At the beginning patients will start on the lowest dose (1 of 3 different levels) of TXSVN. Once that dose schedule proves safe the next group of patients will be started at a higher dose. This process will continue until all 3 dose levels are studied. If the side-effects are too severe the dose will be lowered or the TXSVN administrations will be stopped. Each patient will receive 2 vaccinations at the same dose 2 weeks apart according to the following dosing schedules: The administration will be oral.||Dose Level 1||Day 0: 2 x 10^5 cfu||Day 14: 2 x 10^5 cfu||Dose Level 2||Day 0: 2 x 10^6 cfu||Day 14: 2 x 10^6 cfu||Dose Level 3||Day 0: 2 x 10^7 cfu||Day 14: 2 x 10^7 cfu</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: CVD908ssb-TXSVN</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of patients with dose limiting toxicity (DLT) by CTCAE v5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Incidence of dose limiting toxicities (DLT) of CVD908ssb-TXSVN vaccine in patients with multiple myeloma.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>8 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_26" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive enzalutamide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.|Patients receive enzalutamide as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Enzalutamide; Other: Laboratory Biomarker Analysis; Radiation: Radium Ra 223 Dichloride</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Changes in prostate cancer bone involvement</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be determined by standard pathologic analysis of the biopsies.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 1.5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## FDA APPROVALS ######## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="approvals">Drug Approvals/Applications</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Accutar Biotechnology</td>
    <td>Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_36" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Gracell Biotechnologies</td>
    <td>Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05412329" target="_blank">NCT05412329</a></td><td><select class="form-select" id="select_form_37" name="NCT05412329"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo6" class="accordion-toggle">    <td>Gilead</td>
    <td>FDA Approves Gilead's Trodelvy for HR-Positive HER2-Negative Metastatic Breast Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03901339" target="_blank">TROPiCS-02 (NCT03901339)</a></td><td><select class="form-select" id="select_form_38" name="NCT03901339"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_501" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>bevacizumab</td>
          <td>Avastin</td>
          <td>Genentech Inc.</td>
          <td>2/26/2004</td>
          <td>Intravenous</td>
          <td>['400MG/16ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_503" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>DACOMITINIB</td>
          <td>VIZIMPRO</td>
          <td>PFIZER</td>
          <td>Sep 27 2018</td>
          <td>TABLET;ORAL</td>
          <td>['30MG' '45MG' '15MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_504" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['100MG/4ML (25MG/ML)' '1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_505" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '150MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '150MG/15ML (10MG/ML)' '50MG/5ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['100MG/4ML (25MG/ML)' '1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['500MG/10ML (50MG/ML)' '120MG/2.4ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_506" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['9/4/2014' '1/15/2015']</td>
          <td>Intravenous</td>
          <td>['100MG/4ML (25MG/ML)' '50MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_508" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>ACCORD HLTHCARE</td>
          <td>Aug 3 2017</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/10ML (100MG/ML)' '200MG/2ML (100MG/ML)' '2GM/20ML (100MG/ML)' '1.5GM/15ML (100MG/ML)']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>HOSPIRA INC</td>
          <td>Aug 4 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['1GM/26.3ML (38MG/ML)' '2GM/52.6ML (38MG/ML)' '200MG/5.26ML (38MG/ML)']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMZAR</td>
          <td>LILLY</td>
          <td>May 15 1996</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['EQ 200MG BASE/VIAL' 'EQ 1GM BASE/VIAL']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>INFUGEM</td>
          <td>SUN PHARM</td>
          <td>Jul 16 2018</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)' 'EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)' 'EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)' 'EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)' 'EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)' 'EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)' 'EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)' 'EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)' 'EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)' 'EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)']</td>
            </tr>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['200MG/40ML (5MG/ML)' '50MG/10ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['12/22/2014' '10/4/2017' '8/27/2021']</td>
          <td>Intravenous</td>
          <td>['100MG/10ML' '240MG/24ML' '40MG/4ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_509" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ACYCLOVIR</td>
          <td>AVACLYR</td>
          <td>FERA PHARMS LLC</td>
          <td>Mar 29 2019</td>
          <td>OINTMENT;OPHTHALMIC</td>
          <td>3%</td>
            </tr>
            <tr>
          <td>ACYCLOVIR</td>
          <td>SITAVIG</td>
          <td>EPI HLTH</td>
          <td>Apr 12 2013</td>
          <td>TABLET;BUCCAL</td>
          <td>50MG</td>
            </tr>
            <tr>
          <td>ACYCLOVIR</td>
          <td>ZOVIRAX</td>
          <td>BAUSCH</td>
          <td>['Mar 29 1982' 'Dec 30 2002']</td>
          <td>['OINTMENT;TOPICAL' 'CREAM;TOPICAL']</td>
          <td>5%</td>
            </tr>
            <tr>
          <td>ACYCLOVIR</td>
          <td>ZOVIRAX</td>
          <td>MYLAN</td>
          <td>['Dec 22 1989' 'Jan 25 1985' 'Apr 30 1991']</td>
          <td>['CAPSULE;ORAL' 'TABLET;ORAL' 'SUSPENSION;ORAL']</td>
          <td>['200MG' '800MG' '400MG' '200MG/5ML']</td>
            </tr>
            <tr>
          <td>TEMOZOLOMIDE</td>
          <td>TEMODAR</td>
          <td>MERCK SHARP DOHME</td>
          <td>['Oct 19 2006' 'Aug 11 1999' 'Feb 27 2009']</td>
          <td>['CAPSULE;ORAL' 'POWDER;INTRAVENOUS']</td>
          <td>['180MG' '250MG' '100MG/VIAL' '5MG' '20MG' '100MG' '140MG']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['12/22/2014' '10/4/2017' '8/27/2021']</td>
          <td>Intravenous</td>
          <td>['100MG/10ML' '240MG/24ML' '40MG/4ML' '120MG/12ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_510" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ENZALUTAMIDE</td>
          <td>XTANDI</td>
          <td>ASTELLAS</td>
          <td>['Aug 31 2012' 'Aug 4 2020']</td>
          <td>['CAPSULE;ORAL' 'TABLET;ORAL']</td>
          <td>['80MG' '40MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<center><button type="submit" value="submit">Submit</button></center></div></form><br><p><strong> <em>Disclaimer: This weekly digest is a product created exclusively by Lexidyne LLC, in collaboration with Janssen. The intended purpose is to identify clinical phase assets with new data related to lung cancer, priority mechanisms of action, local/intratumoral delivery, and/or increased potency for acquisition & business development consideration. </em> </strong></p><p><em>Sources used include but are not limited to: PubMed, ClinicalTrials.gov, ASCO, AACR, NIH, EU Clinical Trials Register, European Pharmaceutical Review, FDA.gov, PRNewsWire, FiercePharma, and BioSpace. </em> </p><center><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSffyxD4xZGkc99oZTy9lF0xPdIaqUMfCVpI2lWJzBkH3uDEag/viewform" target="_blank">Subscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdaRqTScaPylLdbIIgAaWs3eYn3wMcF_qF408_-D9caWHAgLw/viewform" target="_blank">Unsubscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdSCfl2l2sV2jo-vFfym-VPpzyEs5M0cRRPY5TmBIZ-nR6gSQ/viewform" target="_blank">Feedback</a></div></center>
